Bank of America Corp DE acquired a new stake in shares of Nightstar Therapeutics PLC (NASDAQ:NITE) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 8,235 shares of the company’s stock, valued at approximately $132,000.
Other large investors have also recently added to or reduced their stakes in the company. Stanley Laman Group Ltd. bought a new stake in Nightstar Therapeutics during the 2nd quarter valued at about $195,000. Millennium Management LLC bought a new stake in Nightstar Therapeutics during the 1st quarter valued at about $507,000. Finally, Woodford Investment Management Ltd bought a new stake in Nightstar Therapeutics during the 2nd quarter valued at about $5,024,000. Institutional investors and hedge funds own 25.49% of the company’s stock.
Shares of NASDAQ NITE opened at $15.01 on Friday. The stock has a market cap of $417.29 million, a PE ratio of -9.21 and a beta of 3.51. Nightstar Therapeutics PLC has a 52-week low of $9.59 and a 52-week high of $29.55.
NITE has been the subject of a number of analyst reports. Cantor Fitzgerald initiated coverage on shares of Nightstar Therapeutics in a research note on Thursday, October 11th. They set an “overweight” rating and a $36.00 price objective for the company. Janney Montgomery Scott initiated coverage on shares of Nightstar Therapeutics in a report on Wednesday, August 22nd. They set a “buy” rating and a $34.00 price target on the stock. BMO Capital Markets set a $41.00 price target on shares of Nightstar Therapeutics and gave the company a “buy” rating in a report on Monday, September 24th. Leerink Swann raised their price target on shares of Nightstar Therapeutics from $30.00 to $35.00 and gave the company a “positive” rating in a report on Monday, September 24th. Finally, Wedbush reaffirmed an “outperform” rating and set a $31.00 price target on shares of Nightstar Therapeutics in a report on Tuesday, September 25th. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Nightstar Therapeutics has an average rating of “Buy” and a consensus target price of $34.43.
TRADEMARK VIOLATION WARNING: “Bank of America Corp DE Acquires Shares of 8,235 Nightstar Therapeutics PLC (NITE)” was originally published by Community Financial News and is the property of of Community Financial News. If you are viewing this news story on another site, it was illegally stolen and republished in violation of United States & international trademark and copyright laws. The original version of this news story can be viewed at https://www.com-unik.info/2018/12/02/bank-of-america-corp-de-acquires-shares-of-8235-nightstar-therapeutics-plc-nite.html.
Nightstar Therapeutics Company Profile
Nightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom. The company's lead product candidate is NSR-REP1, a candidate that is in phase 3 clinical development for the treatment of patients with choroideremia.
Further Reading: What are earnings reports?
Want to see what other hedge funds are holding NITE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nightstar Therapeutics PLC (NASDAQ:NITE).
Receive News & Ratings for Nightstar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nightstar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.